Quick Answer
HALOZYME THERAPEUTICS, INC. reported Common Stock Shares Outstanding of 117.78 million shares for the year ending 2025.
- HALOZYME THERAPEUTICS, INC. showed a decrease of -4.3% in Common Stock Shares Outstanding from 2024 to 2025.
- This data is from HALOZYME THERAPEUTICS, INC.'s annual report (Form 10-K), filed with the SEC on February 17, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), HALOZYME THERAPEUTICS, INC.'s Common Stock Shares Outstanding has grown by 17.1%.
- Historical annual values: Fiscal year 2025: 117.78 million shares | Fiscal year 2024: 123.14 million shares | Fiscal year 2023: 126.77 million shares | Fiscal year 2022: 135.15 million shares | Fiscal year 2021: 137.50 million shares | Fiscal year 2020: 135.03 million shares | Fiscal year 2019: 136.71 million shares | Fiscal year 2018: 144.73 million shares | Fiscal year 2017: 142.79 million shares | Fiscal year 2016: 129.50 million shares | Fiscal year 2015: 128.15 million shares | Fiscal year 2014: 125.72 million shares | Fiscal year 2013: 114.53 million shares | Fiscal year 2012: 112.71 million shares | Fiscal year 2011: 103.99 million shares | Fiscal year 2010: 100.58 million shares.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: